|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.5668 USD | -0.04% |
|
-0.51% | -2.29% |
| Dec. 18 | RTW Biotech Opportunities announces new investment in Yarrow Bioscience | RE |
| Dec. 17 | VYNE Therapeutics Inc., Yarrow Bioscience, Inc. - M&A Call |
Evolution of the Average Target: VYNE Therapeutics Inc.
Evolution of the Target Price: VYNE Therapeutics Inc.
Changes in Analyst Recommendations: VYNE Therapeutics Inc.
772117554b2179d43cc22eb2.FxxwpZ8ap0ysEcX5ptxf7NMXAZ8weHH5zCzof4YwlVk.Q1MK4qx07RzNUvHO37E436FGbal2LESup22ATd98wjNYWzbx93nAf-Vl_Q~61c4b7834a24a28fbbafc3478b9e097d
More recommendations
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | - | +252.86% | ||||
| +18.83% | |||||
| +24.54% | |||||
| +32.54% | |||||
| +26.81% | |||||
| +2.93% | |||||
| -1.58% | |||||
| +42.51% | |||||
| +12.44% | |||||
| +90.29% | |||||
| Average | +50.22% | |||||
| Weighted average by Cap. | +24.58% |
Analysts' Consensus
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
0.5668USD
Average target price
2.000USD
Spread / Average Target
+252.86%
High Price Target
2.000USD
Spread / Highest target
+252.86%
Low Price Target
2.000USD
Spread / Lowest Target
+252.86%
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| BTIG | |
| Cantor Fitzgerald | |
| HC Wainwright | |
| Northland Securities |
SellBuy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
0.5668USD
Average target price
2.000USD
Spread / Average Target
+252.86%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- VYNE Stock
- Consensus VYNE Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
